Search and analyze individual stocks with comprehensive metrics
Dishman Carbogen Amcis Ltd
Fundamental Score
Dishman Carbogen Amcis Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of DCAL across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Attractive Valuation (P/E: 24.96 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Robust Profit Growth (88.81%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Balanced Promoter Holding (59.32%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
8 factors identified
Below-Average Return on Equity (-0.32%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (2.42%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Revenue Contraction (-17.29%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Weak Interest Coverage (1.77x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-69.39 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 9.44%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Dishman Carbogen Amcis Ltd
About DCAL
Business Overview
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Company Details
Key Leadership
Corporate Events
DCAL Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Dishman Carbogen Amcis Ltd (DCAL)?
As of 15 Jan 2026, 04:56 am IST, Dishman Carbogen Amcis Ltd (DCAL) is currently trading at ₹254.65. The stock has a market capitalization of ₹3.73K (Cr).
Is DCAL share price Overvalued or Undervalued?
DCAL is currently trading at a P/E ratio of 24.96x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Dishman Carbogen Amcis Ltd share price?
Key factors influencing DCAL's price include its quarterly earnings growth (Sales Growth: -17.29%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Dishman Carbogen Amcis Ltd a good stock for long-term investment?
Dishman Carbogen Amcis Ltd shows a 5-year Profit Growth of N/A% and an ROE of -0.32%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.40 before investing.
How does Dishman Carbogen Amcis Ltd compare with its industry peers?
Dishman Carbogen Amcis Ltd competes with major peers in the Pharmaceuticals. Investors should compare DCAL's P/E of 24.96x and ROE of -0.32% against the industry averages to determine its competitive standing.
What is the P/E ratio of DCAL and what does it mean?
DCAL has a P/E ratio of 24.96x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹25 for every ₹1 of annual earnings.
How is DCAL performing according to Bull Run's analysis?
DCAL has a Bull Run fundamental score of 30.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does DCAL belong to?
DCAL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Dishman Carbogen Amcis Ltd.
What is Return on Equity (ROE) and why is it important for DCAL?
DCAL has an ROE of -0.32%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Dishman Carbogen Amcis Ltd generates profits from shareholders' equity.
How is DCAL's debt-to-equity ratio and what does it indicate?
DCAL has a debt-to-equity ratio of 0.40, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is DCAL's dividend yield and is it a good dividend stock?
DCAL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has DCAL grown over the past 5 years?
DCAL has achieved 5-year growth rates of: Sales Growth 5.82%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in DCAL and why does it matter?
Promoters hold 59.32% of DCAL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is DCAL's market capitalization category?
DCAL has a market capitalization of ₹3732 crores, placing it in the Small-cap category.
How volatile is DCAL stock?
DCAL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for DCAL?
DCAL has a 52-week high of ₹N/A and low of ₹N/A.
What is DCAL's operating profit margin trend?
DCAL has a 5-year average Operating Profit Margin (OPM) of 14.36%, indicating the company's operational efficiency.
How is DCAL's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -17.29% and YoY Profit Growth of 88.81%.
What is the institutional holding pattern in DCAL?
DCAL has FII holding of 8.07% and DII holding of 1.37%. Significant institutional holding often suggests professional confidence in the stock.